Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

10x Genomics (TXG) EBT (2018 - 2025)

10x Genomics (TXG) has disclosed EBT for 8 consecutive years, with -$15.2 million as the latest value for Q4 2025.

  • Quarterly EBT rose 68.6% to -$15.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$39.9 million through Dec 2025, up 77.54% year-over-year, with the annual reading at -$39.9 million for FY2025, 77.54% up from the prior year.
  • EBT hit -$15.2 million in Q4 2025 for 10x Genomics, up from -$28.2 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $37.0 million in Q2 2025 to a low of -$91.7 million in Q3 2023.
  • Historically, EBT has averaged -$34.1 million across 5 years, with a median of -$35.8 million in 2024.
  • Biggest five-year swings in EBT: tumbled 541.0% in 2022 and later soared 199.78% in 2025.
  • Year by year, EBT stood at -$16.0 million in 2021, then fell by 2.61% to -$16.4 million in 2022, then tumbled by 183.94% to -$46.6 million in 2023, then fell by 3.82% to -$48.4 million in 2024, then soared by 68.6% to -$15.2 million in 2025.
  • Business Quant data shows EBT for TXG at -$15.2 million in Q4 2025, -$28.2 million in Q3 2025, and $37.0 million in Q2 2025.